Phase 1 Plasma Cell Leukemia Clinical Trials
5 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–5 of 5 trials
Recruiting
Phase 1Phase 2
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
Hodgkin LymphomaMultiple MyelomaAcute Myeloid Leukemia (AML)+7 more
M.D. Anderson Cancer Center80 enrolled1 locationNCT05092451
Recruiting
Phase 1Phase 2
Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
Peripheral T Cell LymphomaT-lymphoblastic LymphomaRelapsed/Refractory B-cell Acute Lymphoblastic Leukemia+4 more
Beijing Biotech96 enrolled1 locationNCT07523555
Recruiting
Phase 1Phase 2
Autologous Transplantation Combined With BCMA CAR-T in the Treatment of UHR-MM
Plasma Cell LeukemiaUltra High Risk mm (uhr-mm), 18-70 Years Old, Suitable for ASCT. And Meet Any of the Following uhr-mm DefinitionsCytogenetics Ultra High Risk+4 more
Institute of Hematology & Blood Diseases Hospital, China50 enrolled1 locationNCT07109323
Recruiting
Phase 1
A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
Plasma Cell LeukemiaRelapsed/Refractory Multiple Myeloma
Chunrui Li18 enrolled1 locationNCT05219721
Recruiting
Phase 1
A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
Plasma Cell LeukemiaRelapsed/Refractory Multiple Myeloma
Nanjing IASO Biotechnology Co., Ltd.12 enrolled1 locationNCT05759793